CATEGORY 1

REGULATORY INFORMATION DISTRIBUTION SYSTEM (RIDS)

ACCESSION NBR:9612090341 DOC.DATE: 96/12/02 NOTARIZED: NO DOCKET #

FACIL:50-269	Oconee Nuclear Station, Unit 1, Duke Power Co.	05000269
50-270	Oconee Nuclear Station, Unit 2, Duke Power Co.	05000270
50-287	Oconee Nuclear Station, Unit 3, Duke Power Co.	05000287
50-369	William B. McGuire Nuclear Station, Unit 1, Duke Powe	05000369
50-370	William B. McGuire Nuclear Station, Unit 2, Duke Powe	05000370
50-413	Catawba Nuclear Station, Unit 1, Duke Power Co.	05000413
50-414	Catawba Nuclear Station, Unit 2, Duke Power Co.	05000414

AUTH.NAME AUTHOR AFFILIATION
TUCKMAN,M.S. Duke Power Co.
RECIP.NAME RECIPIENT AFFILIATION
Document Control Branch (Document Control Desk)

SUBJECT: Forwards unsatisfactory performance test results for FFD program for plants.

DISTRIBUTION CODE: A022D COPIES RECEIVED:LTR 1 ENCL 1 SIZE: 5
TITLE: Fitness for Duty Program: Blind Performance Test/Other

NOTES:

	RECIPIENT ID CODE/NAME	COPIES LTTR	COPIES ENCL	RECIPIENT ID CODE/NAME	COPIES LTTR	COPIES ENCL
	PD2-2 PD	1	1	LABARGE,D	1	1
	NERSES,V	1	1	TAM,P.	1	1
INTERNAL:	ACRS	1	1	FILE CENTER 01	1	1
	NRR/DRPM/PERB	1	1	NRR/DRPM/PSGB	1	1
	NUDOCS-ABSTRACT	1	1	RGN2	1	1
EXTERNAL:	NOAC	1	1	NRC PDR	1	1

C A T E G O R Y 1 D O C U M E N T

NOTE TO ALL "RIDS" RECIPIENTS:
PLEASE HELP US TO REDUCE WASTE! CONTACT THE DOCUMENT CONTROL DESK, ROOM OWFN 5D-5(EXT. 415-2083) TO ELIMINATE YOUR NAME FROM DISTRIBUTION LISTS FOR DOCUMENTS YOU DON'T NEED!

TOTAL NUMBER OF COPIES REQUIRED: LTTR 12 ENCL 12

Duke Power Company
P.O. Box 1006
Charlotte, NC 28201-1006

M. S. TUCKMAN
Senior Vice President
Nuclear Generation
(704)382-2200 Office
(704)382-4360 Fax

DUKE POWER

December 2, 1996

U. S. Nuclear Regulatory Commission
Attn: Document Control Desk
Washington, D. C. 20555

Subject: Fitness-For-Duty Program
Unsatisfactory Performance Test Result

Oconee Nuclear Station
Docket Numbers 50-269, -270 and -287
McGuire Nuclear Station
Docket Numbers 50-369 and -370
Catawba Nuclear Station
Docket Numbers 50-413 and -414

Attached is a report, as required by 10CFR 26, Appendix A, of unsatisfactory performance test results.

If there are any questions, please contact G. A. Copp at (704)382-5826.

Very truly yours,

M. S. Tuckman

M. S. Tuckman

9612090341 961202
PDR ADOCK 05000269
R PDR

A022 1/1

090062

Printed on recycled paper

Mr. Victor Nerses, Project Manager
Office of Nuclear Reactor Regulation
U. S. Nuclear Regulatory Commission
Mail Stop 14H25, OWFN
Washington. D. C. 20555

Mr. Peter S. Tam, Project Manager
Office of Nuclear Reactor Regulation
U. S. Nuclear Regulatory Commission
Mail Stop 14H25, OWFN
Washington, D. C. 20555

Mr. D. E. Lebarge, Project Manager
Office of Nuclear Reactor Regulation
U. S. Nuclear Regulatory Commission
Washington. D. C. 20555

Mr. S. D. Ebneter, Regional Administrator
U. S. Nuclear Regulatory Commission - Region II
101 Marietta Street, NW - Suite 2900
Atlanta, GA 30323

Duke Power Company
Health & Safety Division
P.O. Box 1006 (EC02O)
Charlotte, NC 28201-1006

DUKE POWER

November 25, 1996

SUBJECT: False Negative Blind Urine Drug Screen

A blind specimen spiked with amphetamine was identified as negative by the SmithKline Beecham Laboratory in Atlanta. The specimen was submitted from McGuire Nuclear Station in September, 1996.

Dr. Jerry McHan of Quality Assurance Associates notified me of the results on November 8, 1996. Dr. McHan has investigated the result with Dr. Feldman of the laboratory. A report from Dr. Feldman is attached.

The laboratory correctly identified 6 of 7 specimens spiked with amphetamine in the 3rd quarter of 1996. The one missed was just under the cutoff level.

William E. Dukes, Jr., MD

William E. Dukes, Jr., MD
Corporate Medical Director

WED/sap
Enclosure

Printed on recycled paper

SmithKline Beecham
Clinical Laboratories

Dr. Gene Dukes
Corporate Medical Director
Duke Power Company
422 S. Church St.
Charlotte, NC 28242

Nov. 18, 1996,

Re: Blind QC Audit, 646615J

Dear Dr. Dukes:

The above specimen was reported as negative, based on an amphetamine screening result of 0.884 (1.000 is cutoff).

At the end of spring, the new J1 lot of Behring (Syva) amphetamine reagent replaced our old lot, and was verified for acceptible reactivity to d-methamphetamine and d-amphetamine on our AU5000 screening instruments. Over the summer, our Olympus AU5000 screening instruments were replaced with new AU800 instruments. Although the AU800s were properly validated for the amphetamines class with d-methamphetamine calibrator and control materials, the reactivity for d-amphetamine was not checked. Behring's own d-amphetamine studies were performed only on AU5000 instruments.

In response to your feedback, we have checked the four AU800s, and they give appropriate response for d-amphetamine, however there is variation between the instruments. We have looked at the AU800 screening results from other blind QC samples that were properly reported as positive, and at negative urine samples spiked with 1500 ng/ml d-amphetamine. All gave similar positive screening results, and similar GC/MS concentrations. The control data from the original screening load for the above specimen gives no indication of a reagent or instrument problem.

The reagent manufacturer has standardized their amphetamines kit with d-methamphetamine and supplies us with d-methamphetamine as the calibrator. Our high and low controls contain d-methamphetamine. Although the manufacturer claims to have equal response to d-amphetamine, there will always be some variability in the exact cross-reactivity. In order to monitor this more closely, we are including d-amphetamine in one of our batch controls.

1777 Montreal Circle • Tucker, GA 30084 • (770) 934-9200

This should prevent the re-occurence of failing to detect d-amphetamine spiked samples. If you have any questions, call me at (770)452-1590.

Sincerely yours,

Michael S. Feldman, PhD
Technical Manager, Substance Abuse Testing

cc: J. McHan, PhD